


In *Z Orthop Unfall*. 2022. doi:10.1055/a-1663-6807

Recommendation of the Working Group Tissue Regeneration of the German Orthopedic and Trauma Society (DGOU) for Treatment of Focal Cartilage Defects of the Knee Joint

Authors

Philipp Niemeyer, Dirk Albrecht, Matthias Aurich, Christoph Becher, Peter Behrens, Peter Bichmann, Gerrit Bode, Peter Brucker, Christoph Erggelet, Marco Ezechieli, Svea Faber, Stefan Fickert, Jürgen Fritz, Arnd Hoburg, Peter Kreuz, Jörg Lützner, Henning Madry, Stefan Marlovits, Julian Mehl, Peter E Müller, Stefan Nehrer, Thomas Niethammer, Matthias Pietschmann, Christian Plaass, Philip Rössler, Klaus Rhunau, Bernhard Schewe, Gunter Spahn, Matthias Steinwachs, Thomas Tischer, Martin Volz, Markus Walther, Wolfgang Zinser, Johannes Zellner, Peter Angele

Defect size-dependent indications for various cartilage regenerative therapies



A symptomatic, full-thickness, focal cartilage defect in the absence of osteoarthritis represents the classic indication for cartilage regenerative therapy.

*The majority of published cases (Massen et al., 2019) were covered with the Chondro-Gide[®] membrane.

New features compared to previous guidelines

- > Matrix-augmented bone marrow stimulation (mBMS), such as the AMIC[®] procedure, has been included in the recommendation as a standard method for treatment of **chondral defects** from 1–4.5 cm² as well as for **osteochondral defects** from 0–4 cm².
- > For the first time, a subdivision in **recommended standard methods** and **methods with potential** but not yet sufficient scientific evidence was made.
- > For these recommendations, a **strict separation** of purely **chondral** and **osteochondral defects** with **separately assigned suitable treatment options** was introduced.
- > **Focal degenerative** cartilage damage was classified as **suitable** for surgical treatment.
- > An **axial deviation >5°** remains a **contraindication** for cartilage regenerative therapy despite a trend to correction of even smaller deviations.
- > ICRS grade I and II lesions on corresponding joint surfaces are no longer considered a contraindication even without supplementary treatment.
- > Cartilage regenerative surgery in case of **substantially reduced meniscal tissue** continues to be classified as **critical**.

NEW:
AMIC[®]/mBMS is now included as a standard method in cartilage regenerative treatment recommendations.

FACT:
The best evidence currently available within the group of mBMS is for the use of the Chondro-Gide[®] membrane (AMIC[®] procedure).



Link to publication

CHONDRO-GIDE® LITERATURE HIGHLIGHT

This literature highlight addresses important aspects of the evidence for the use of Chondro-Gide®.

XPERIENCE THE EVIDENCE

100+ peer-reviewed publications

AMIC® Chondro-Gide®

- > Combines bone marrow stimulating techniques with the collagen membrane¹
- > Compatible with a range of cost-efficient, one-step cartilage regeneration techniques^{2,3,4}
- > Stable results over 10+ years⁵
- > More than 15 years of clinical success
- > Biocompatible and naturally resorbed¹



www.geistlich-surgery.com

Headquarter Switzerland
Geistlich Pharma AG
Business Unit Surgery
Bahnhofstrasse 40
CH-6110 Wolhusen
Phone +41 41 492 55 55
Fax +41 41 492 56 39
surgery@geistlich.com
www.geistlich-surgery.com



- 1 Geistlich Pharma AG, data on file (bench tests and pre-clinical studies)
- 2 Kramer J, et al., *Cell Mol Life Sci.* 2006 Mar;63(5):616-26. (Clinical study)
- 3 Walther M, et al., *Oper Orthop Traumatol.* 2014 Dec;26(6):603-10. (Clinical study)
- 4 Fossum V, et al., *Orthop J Sports Med.* 2019 Sep;7(9):2325967119868212. (Clinical study)
- 5 Kaiser N, et al., *Arch Orthop Trauma Surg.* 2021 Nov;141(11):1845-54. (Clinical study)